atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
atai Life Sciences N.V (ATAI) PT Lowered to $5 at Jefferies
August 13, 2024 4:04 PM EDTJefferies analyst Andrew Tsai lowered the price target on atai Life Sciences N.V (NASDAQ: ATAI) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "ATAI's pipeline of psychedelics (and non-psychedelics) has pot'l to safely, profoundly, and durably treat tough $1B+... More
